Skip to main content
PMC home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2007 Oct;4(4):590–601. doi: 10.1016/j.nurt.2007.07.004

Chemokines and chemokine receptors in neurological disease: Raise, retain, or reduce?

Carine Savarin-Vuaillat 1, Richard M Ransohoff 1,✉
PMCID: PMC7479679  PMID: 17920540

Summary

Chemokines and chemokine receptors comprise a large number of molecules implicated in a wide range of physiological and pathological functions. Numerous studies have demonstrated the roles of chemokines and chemokine receptors: 1) during development, by regulating hematopoiesis, cardiogenesis, and vascular and cerebellar development; 2) during tumor biology, by controlling cell proliferation, angiogenesis, and metastasis; and 3), especially during leukocyte migration, by acting on firm adhesion, locomotion, diapedesis, and chemotaxis. This review focuses on chemokine and chemokine receptor involvement in diverse neurological diseases and their therapeutic potentials. Because of its induction or upregulation during CNS pathologies, members of the chemokine system can be used as biological markers. CXCR4 and CXCL12, by the correlation between their expression and the glioblastoma tumor progression, could be a marker to grade this type of CNS tumor. CCR1, by virtue of specific expression in Aβ plaques, may be a marker for Alzheimer pathology. Downregulation of CCL2 in cerebrospinal fluid may be a candidate to characterize multiple sclerosis (MS), but needs additional investigation. Moreover, chemokines and chemokine receptors represent interesting therapeutic targets. Using chemokine receptor antagonists, several studies provided exciting findings for potential neurological disease treatment. Chemokine receptor antagonists reduce disease severity in animal models of MS. In glioblastoma, a CXCR4 antagonist (AMD3100) showed an inhibition of tumor growth. Inhibition of chemokine receptor signaling is not the only therapeutic strategy: for example, CXCR4-CXCL12 has anti-inflammatory properties and CX3CL1-CX3CR1 controls neurotoxicity. Thus, chemokine biology suggests several approaches for treating neurological disease.

Key Words: Chemokines, chemokine receptors, neurological disease, cell trafficking, marker, antagonist

References

  • 1.Yoshimura T, Matsushima K, Tanaka S, et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci U S A. 1987;84:9233–9237. doi: 10.1073/pnas.84.24.9233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI. Structure and functional expression of a human interleukin-8 receptor. Science. 1991;253:1278–1280. doi: 10.1126/science.1840701. [DOI] [PubMed] [Google Scholar]
  • 3.Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–127. doi: 10.1016/S1074-7613(00)80165-X. [DOI] [PubMed] [Google Scholar]
  • 4.Luster AD. Chemokines: chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436–445. doi: 10.1056/NEJM199802123380706. [DOI] [PubMed] [Google Scholar]
  • 5.Laing KJ, Secombes CJ. Chemokines. Dev Comp Immunol. 2004;28:443–460. doi: 10.1016/j.dci.2003.09.006. [DOI] [PubMed] [Google Scholar]
  • 6.Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev. 1999;10:61–86. doi: 10.1016/S1359-6101(99)00005-2. [DOI] [PubMed] [Google Scholar]
  • 7.Keiner GS, Kennedy J, Bacon KB, et al. Lymphotactin: a cytokine that represents a new class of chemokine. Science. 1994;266:1395–1399. doi: 10.1126/science.7973732. [DOI] [PubMed] [Google Scholar]
  • 8.Bazan JF, Bacon KB, Hardiman G, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385:640–644. doi: 10.1038/385640a0. [DOI] [PubMed] [Google Scholar]
  • 9.Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610–621. doi: 10.1056/NEJMra052723. [DOI] [PubMed] [Google Scholar]
  • 10.Clark-Lewis I, Kim KS, Rajarathnam K, et al. Structure-activity relationships of chemokines. J Leukoc Biol. 1995;57:703–711. doi: 10.1002/jlb.57.5.703. [DOI] [PubMed] [Google Scholar]
  • 11.Cartier L, Hartley O, Dubois-Dauphin M, Krause KH. Chemokine receptors in the central nervous system: role in brain inflammation and neurodegenerative diseases. Brain Res Brain Res Rev. 2005;48:16–42. doi: 10.1016/j.brainresrev.2004.07.021. [DOI] [PubMed] [Google Scholar]
  • 12.Mellado M, Rodríguez-Frade JM, Manes S, Martmez-A C. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu Rev Immunol. 2001;19:397–421. doi: 10.1146/annurev.immunol.19.1.397. [DOI] [PubMed] [Google Scholar]
  • 13.Vroon A, Heijnen CJ, Kavelaars A. GRKs and arrestins: regulators of migration and inflammation. J Leukoc Biol. 2006;80:1214–1221. doi: 10.1189/jlb.0606373. [DOI] [PubMed] [Google Scholar]
  • 14.Imhof BA, Engelhardt B, Vadas M. Novel mechanisms of the transendothelial migration of leukocytes. Trends Immunol. 2001;22:411–414. doi: 10.1016/S1471-4906(01)01961-5. [DOI] [PubMed] [Google Scholar]
  • 15.Engelhardt B, Ransohoff RM. The ins and outs of T lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol. 2005;26:485–495. doi: 10.1016/j.it.2005.07.004. [DOI] [PubMed] [Google Scholar]
  • 16.Middleton J, Patterson AM, Gardner L, Schmutz C, Ashton BA. Leukocyte extravasation: chemokine transport and presentation by the endothelium. Blood. 2002;100:3853–3860. doi: 10.1182/blood.V100.12.3853. [DOI] [PubMed] [Google Scholar]
  • 17.Schreiber TH, Shinder V, Cain DW, Alon R, Sackstein R. Shear flow-dependent integration of apical and subendothelial chemokines in T-cell transmigration: implications for locomotion and the multistep paradigm. Blood. 2007;109:1381–1386. doi: 10.1182/blood-2006-07-032995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Le Y, Zhou Y, Iribarren P, Wang JM. Chemokines and chemokine receptors: their manifold role in homeostasis and disease. Cell Mol Immunol. 2004;1:95–104. [PubMed] [Google Scholar]
  • 19.Mackay CR. Chemokines: immunology’s high impact factors. Nat Immunol. 2001;2:95–101. doi: 10.1038/84298. [DOI] [PubMed] [Google Scholar]
  • 20.Nakano H, Mori S, Yonekawa H, Nariuchi H, Matsuzawa A, Kakiuchi T. A novel mutant gene involved in T-lymphocyte-specific homing into peripheral lymphoid organs on mouse chromosome 4. Blood. 1998;91:2886–2895. [PubMed] [Google Scholar]
  • 21.Forster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell. 1996;188:373–386. doi: 10.1016/s0092-8674(00)81798-5. [DOI] [PubMed] [Google Scholar]
  • 22.Gerhardt CC, Romero IA, Cancello R, Camoin L, Strosberg AD. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol. 2001;175:81–92. doi: 10.1016/S0303-7207(01)00394-X. [DOI] [PubMed] [Google Scholar]
  • 23.Reddy S, Bai Y, Robinson E, Ross J. Immunolocalization of monocyte chemoattractant protein-1 in islets of NOD mice during cyclophosphamide administration. Ann N Y Acad Sci. 2006;1079:103–108. doi: 10.1196/annals.1375.014. [DOI] [PubMed] [Google Scholar]
  • 24.Kanda N, Shimizu T, Tada Y, Watanabe S. IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10 and CXCL11 in human keratinocytes. Eur J Immunol. 2007;37:338–350. doi: 10.1002/eji.200636420. [DOI] [PubMed] [Google Scholar]
  • 25.Tachibana K, Hirota S, Lizasa H, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998;393:591–594. doi: 10.1038/31261. [DOI] [PubMed] [Google Scholar]
  • 26.Zou YR, Kottman AH, Kuroda M, Taniuchi I, Littman D. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998;393:595–599. doi: 10.1038/31269. [DOI] [PubMed] [Google Scholar]
  • 27.Bendall L. Chemokines and their receptors in disease. Histol Histopathol. 2005;20:907–926. doi: 10.14670/HH-20.907. [DOI] [PubMed] [Google Scholar]
  • 28.Burger M, Burger JA, Hoch RC, Oades Z, Takamori H, Schraufstatter IU. Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi’s sarcoma herpes virus-G protein-coupled receptor. J Immunol. 1999;163:2017–2022. [PubMed] [Google Scholar]
  • 29.Luca M, Huang S, Gershenwald J, Singh R, Reich R, Bar-Eli M. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am J Pathol. 1997;151:1105–1113. [PMC free article] [PubMed] [Google Scholar]
  • 30.Inoue K, Slaton J, Eve B, et al. Interleukin-8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin Cancer Res. 2000;6:2104–2119. [PubMed] [Google Scholar]
  • 31.Darash-Yahana M, Pikarsky E, Abramovitch R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization and metastasis. FASEB J. 2004;18:1240–1242. doi: 10.1096/fj.03-0935fje. [DOI] [PubMed] [Google Scholar]
  • 32.Kawada K, Hosogi H, Sonoshita M, et al. Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene. 2007;26:4679–4688. doi: 10.1038/sj.onc.1210267. [DOI] [PubMed] [Google Scholar]
  • 33.Dziembowska M, Tham TN, Lau P, Vitry S, Lazarini F, Dubois-Dalcq M. A role of CXCR4 signaling in survival and migration of neural and oligodendrocyte precursors. Glia. 2005;50:258–269. doi: 10.1002/glia.20170. [DOI] [PubMed] [Google Scholar]
  • 34.Tsai HH, Frost E, To V, et al. The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell. 2002;110:373–383. doi: 10.1016/S0092-8674(02)00838-3. [DOI] [PubMed] [Google Scholar]
  • 35.Padovani-Claudio DA, Liu L, Ransohoff RM, Miller RH. Alterations in the oligodendrocyte lineage, myelin and white matter in adult mice lacking the chemokine receptor CXCR2. Glia. 2006;54:471–483. doi: 10.1002/glia.20383. [DOI] [PubMed] [Google Scholar]
  • 36.Giovannelli A, Limatola C, Ragozzino D, et al. CXC chemokines interleukin-8 (IL8) and growth-related gene product α (GROα) modulate Purkinje neuron activity in mouse cerebellum. J Neuroimmunol. 1998;92:122–132. doi: 10.1016/S0165-5728(98)00192-1. [DOI] [PubMed] [Google Scholar]
  • 37.Limatola C, Giovanelli A, Maggi L, et al. SDF-1α-mediated modulation of synaptic transmission in rat cerebellum. Eur J Neurosci. 2000;12:2497–2504. doi: 10.1046/j.1460-9568.2000.00139.x. [DOI] [PubMed] [Google Scholar]
  • 38.Bertollini C, Ragozzino D, Gross C, Limatola C, Eusebi F. Frac-talkine/CX3CL1 depresses central synaptic transmission in mouse hippocampal slices. Neuropharmacology. 2006;51:816–821. doi: 10.1016/j.neuropharm.2006.05.027. [DOI] [PubMed] [Google Scholar]
  • 39.Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci. 2006;27:48–55. doi: 10.1016/j.tips.2005.11.002. [DOI] [PubMed] [Google Scholar]
  • 40.Rempel SA, Dudas S, Ge S, Gutierrez JA. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res. 2000;6:102–111. [PubMed] [Google Scholar]
  • 41.Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50–56. doi: 10.1038/35065016. [DOI] [PubMed] [Google Scholar]
  • 42.Bartolome RA, Galvez BG, Longo N, et al. Stromal cell-derived factor-1α promotes melanoma cell invasion across basement membranes involving stimulation of membrane-type 1 matrix metalloproteinase and Rho GTPase activities. Cancer Res. 2004;64:2534–2543. doi: 10.1158/0008-5472.CAN-03-3398. [DOI] [PubMed] [Google Scholar]
  • 43.Singh S, Singh UP, Grizzle WE, Lillard JW. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion. Lab Invest. 2004;84:1666–1676. doi: 10.1038/labinvest.3700181. [DOI] [PubMed] [Google Scholar]
  • 44.Ehtesham M, Winston JA, Kabos P, Thompson RC. CXCR4 expression mediates glioma cell invasiveness. Oncogene. 2006;25:2801–2806. doi: 10.1038/sj.onc.1209302. [DOI] [PubMed] [Google Scholar]
  • 45.Zhou Y, Larsen PH, Hao C, Yong VW. CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J Biol Chem. 2002;277:49481–49487. doi: 10.1074/jbc.M206222200. [DOI] [PubMed] [Google Scholar]
  • 46.Sehgal A, Boynton AL, Young RF, et al. Application of the differential hybridization of Atlas human expression arrays technique in the identification of differentially expressed genes in human glioblastoma multiforme tumor tissue. J Surg Oncol. 1998;67:234–242. doi: 10.1002/(SICI)1096-9098(199804)67:4<234::AID-JSO5>3.0.CO;2-9. [DOI] [PubMed] [Google Scholar]
  • 47.Sehgal A, Ricks S, Boynton A, Warrick J, Murphy GP. Molecular characterization of CXCR4: a potential brain tumor-associated gene. J Surg Oncol. 1998;69:239–248. doi: 10.1002/(SICI)1096-9098(199812)69:4<239::AID-JSO9>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  • 48.Salmaggi A, Gelati M, Polio B, et al. CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. J Neurooncol. 2005;74:287–293. doi: 10.1007/s11060-004-7327-y. [DOI] [PubMed] [Google Scholar]
  • 49.Xia MQ, Qin SX, Wu LJ, Mackay CR, Hyman BT. Immunohistochemical study of the beta-chemokine receptors CCR3 and CCR5 and their ligands in normal and Alzheimer’s disease brains. Am J Pathol. 1998;153:31–37. doi: 10.1016/S0002-9440(10)65542-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Xia MQ, Bacskai BJ, Knowles RB, Qin SX, Hyman BT. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer’s disease. J Neuroimmunol. 2000;108:227–235. doi: 10.1016/S0165-5728(00)00285-X. [DOI] [PubMed] [Google Scholar]
  • 51.Xia M, Hyman BT. GROα/KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation: a role in Alzheimer’s disease? J Neuroimmunol. 2002;122:55–64. doi: 10.1016/S0165-5728(01)00463-5. [DOI] [PubMed] [Google Scholar]
  • 52.Ishizuka K, Kimura T, Igata-yi R, Katsuragi S, Takamatsu J, Miyakawa T. Identification of monocytes chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer’s disease. Psychiatry Clin Neurosci. 1997;51:135–138. doi: 10.1111/j.1440-1819.1997.tb02375.x. [DOI] [PubMed] [Google Scholar]
  • 53.Streit WJ, Conde JR, Harrison JK. Chemokines and Alzheimer’s disease. Neurobiol Aging. 2001;22:909–913. doi: 10.1016/S0197-4580(01)00290-1. [DOI] [PubMed] [Google Scholar]
  • 54.Halks-Miller M, Schroeder ML, Haroutunian V, et al. CCR1 is an early and specific marker of Alzheimer’s disease. Ann Neurol. 2003;54:638–646. doi: 10.1002/ana.10733. [DOI] [PubMed] [Google Scholar]
  • 55.Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry. 2002;10:24–35. [PubMed] [Google Scholar]
  • 56.Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol. 2004;55:306–319. doi: 10.1002/ana.20009. [DOI] [PubMed] [Google Scholar]
  • 57.Verhoeff NP, Wilson AA, Takeshita S, et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. Am J Geriatr Psychiatry. 2004;12:584–595. doi: 10.1176/appi.ajgp.12.6.584. [DOI] [PubMed] [Google Scholar]
  • 58.Trebst C, Ransohoff RM. Investigating chemokines and chemokine receptors in patients with multiple sclerosis. 2001;58:1975–1980. doi: 10.1001/archneur.58.12.1975. [DOI] [PubMed] [Google Scholar]
  • 59.Balashov KE, Rottman JB, Weiner HL, Hancock VW. CCR5+ and CXCR3+ T cells are increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions. Roc Natl Acad Sci U S A. 1999;96:6873–6878. doi: 10.1073/pnas.96.12.6873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Lund BT, Ashikian N, Ta HQ, et al. Increased CXCL8 (IL-8) expression in multiple sclerosis. J Neuroimmunol. 2004;155:161–171. doi: 10.1016/j.jneuroim.2004.06.008. [DOI] [PubMed] [Google Scholar]
  • 61.Teleshova N, Pashenkov M, Huang YM, et al. Multiple sclerosis and optic neuritis: CCR5 and CXCR3 expressing T cells are augmented in blood and cerebrospinal fluid. J Neurol. 2002;249:723–729. doi: 10.1007/s00415-002-0699-z. [DOI] [PubMed] [Google Scholar]
  • 62.Trebst C, Sorensen TL, Kivisakk P, et al. CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol. 2001;159:1701–1710. doi: 10.1016/S0002-9440(10)63017-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Sorensen TL, Tani M, Jensen J, et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 1999;103:807–815. doi: 10.1172/JCI5150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Mahad D, Callahan MK, Williams KA, et al. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain. 2006;129:212–223. doi: 10.1093/brain/awh655. [DOI] [PubMed] [Google Scholar]
  • 65.Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassman H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707–717. doi: 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  • 66.Mahad DJ, Trebst C, Kivisakk P, et al. Expression of chemokine receptors CCR1 and CCR5 reflect differential activation of mononuclear phagocytes in pattern II and pattern III multiple sclerosis lesions. J Neuropathol Exp Neurol. 2004;63:262–273. doi: 10.1093/jnen/63.3.262. [DOI] [PubMed] [Google Scholar]
  • 67.Infante-Duarte C, Weber A, Kratzschmar J, et al. Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB J. 2005;19:1902–1904. doi: 10.1096/fj.05-3832fje. [DOI] [PubMed] [Google Scholar]
  • 68.Sellebjerg F, Madsen HO, Jensen CV, Jensen J, Garred P. CCR5A32, matrix metalloproteinase-9 and disease activity in multiple sclerosis. J Neuroimmunol. 2000;102:98–106. doi: 10.1016/S0165-5728(99)00166-6. [DOI] [PubMed] [Google Scholar]
  • 69.Gade-Andavolu R, Comings DE, MacMurray J, et al. Association of CCR5Δ32 deletion with early death in multiple sclerosis. Genet Med. 2004;6:126–131. doi: 10.1097/01.GIM.0000127274.45301.54. [DOI] [PubMed] [Google Scholar]
  • 70.Kantor R, Bakhanashvili M, Achiron A. A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology. 2003;61:238–240. doi: 10.1212/01.wnl.0000069921.20347.9e. [DOI] [PubMed] [Google Scholar]
  • 71.Kantarci OH, Morales Y, Ziemer PA, et al. CCR5A32 polymorphism effects on CCR5 expression, patterns of immunopathology and disease course in multiple sclerosis. J Neuroimmunol. 2005;169:137–143. doi: 10.1016/j.jneuroim.2005.07.025. [DOI] [PubMed] [Google Scholar]
  • 72.Rottman JB, Slavin AJ, Weiner HL, Gerard CG, Hancock WW. Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol. 2000;30:2372–2377. doi: 10.1002/1521-4141(2000)30:8<2372::AID-IMMU2372>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  • 73.Liang M, Mallari C, Rosser M, et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem. 2000;275:19000–19008. doi: 10.1074/jbc.M001222200. [DOI] [PubMed] [Google Scholar]
  • 74.Zipp F, Hartung HP, Hillert J, et al. Blockade of chemokine signaling in patients with multiple sclerosis. Neurology. 2006;67:1880–1883. doi: 10.1212/01.wnl.0000244420.68037.86. [DOI] [PubMed] [Google Scholar]
  • 75.Ge Y. Seeing is believing: in vivo evolution of multiple sclerosis pathology with magnetic resonance. Top Magn Reson Imaging. 2006;17:295–306. doi: 10.1097/RMR.0b013e3180417d14. [DOI] [PubMed] [Google Scholar]
  • 76.Izikson L, Klein RS, Charo IF, Weiner HL, Luster A. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J Exp Med. 2000;192:1075–1080. doi: 10.1084/jem.192.7.1075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Brodmerkel CM, Huber R, Covington M, et al. Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344. J Immunol. 2005;175:5370–5378. doi: 10.4049/jimmunol.175.8.5370. [DOI] [PubMed] [Google Scholar]
  • 78.Barber CG. CCR5 antagonists for the treatment of HIV. Curr Opin Investig Drugs. 2004;5:851–861. [PubMed] [Google Scholar]
  • 79.Tran EH, Kuziel WA, Owens T. Induction of experimental autoimmune encephalomyelitis in C57B1/6 mice deficient in either the chemokine macrophage inflammatory protein-1α or its CCR5 receptor. Eur J Immunol. 2000;30:1410–1415. doi: 10.1002/(SICI)1521-4141(200005)30:5<1410::AID-IMMU1410>3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
  • 80.Matsui M, Weaver J, Proudfoot A, et al. Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES. J Neuroimmunol. 2002;128:16–33. doi: 10.1016/S0165-5728(02)00121-2. [DOI] [PubMed] [Google Scholar]
  • 81.Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol. 2000;48:893–901. doi: 10.1002/1531-8249(200012)48:6<893::AID-ANA10>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  • 82.Liu L, Huang D, Matsui M, et al. Severe disease, unaltered leukocyte migration, and reduced IFN-γ production in CXCR3−/− mice with experimental autoimmune encephalomyelitis. J Immunol. 2006;176:4399–4409. doi: 10.4049/jimmunol.176.7.4399. [DOI] [PubMed] [Google Scholar]
  • 83.Rubin JB, Kung AL, Klein RS, et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A. 2003;100:13513–13518. doi: 10.1073/pnas.2235846100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 84.McCandless EE, Wang Q, Woerner BM, Harper JM, Klein RS. CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J Immunol. 2006;177:8053–8064. doi: 10.4049/jimmunol.177.11.8053. [DOI] [PubMed] [Google Scholar]
  • 85.Combs CK, Karlo JC, Kao SC, Landreth GE. Beta-amyloid stimulation of microglia and monocytes in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J Neurosci. 2001;21:1179–1188. doi: 10.1523/JNEUROSCI.21-04-01179.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 86.Zujovic V, Benavides J, Vigé X, Carter C, Taupin V. Fractalkine modulates TNF-α secretion and neurotoxicity induced by microglial activation. Glia. 2000;29:305–315. doi: 10.1002/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
  • 87.Cardona AE, Pioro EP, Sasse ME, et al. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci. 2006;9:917–924. doi: 10.1038/nn1715. [DOI] [PubMed] [Google Scholar]
  • 88.Huang D, Shi FD, Jung S, et al. The neuronal chemokine CX3CL1/ fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J. 2006;20:896–905. doi: 10.1096/fj.05-5465com. [DOI] [PubMed] [Google Scholar]
  • 89.Wells TNC, Power CA, Shaw JP, Proudfoot AEI. Chemokine blockers: therapeutics in the making? Trends Pharmacol Sci. 2006;27:41–47. doi: 10.1016/j.tips.2005.11.001. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES